Related Experiment Video

Updated: May 9, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Association between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a

Jun Wang1, Xufeng Guo, Pengbo Wu

  • 1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Gene
|July 30, 2013
PubMed

Keywords:
CIHWEHardy–Weinberg equilibriumMSMeta-analysisNAFLDNASHNon-alcoholic fatty liver diseaseORPPAR-γPolymorphismSNPconfidence intervalmetabolic syndromenon-alcoholic fatty liver diseasenon-alcoholic steatohepatitisodds ratioperoxisome proliferator activated receptor-γsingle nucleotide polymorphism

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Concept Videos

Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...